Zevra Therapeutics, Inc.ZVRANASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank38
3Y CAGR-13.7%
5Y CAGR+7.6%
Year-over-Year Change
Research and development spending
3Y CAGR
-13.7%/yr
vs -17.0%/yr prior
5Y CAGR
+7.6%/yr
Recent deceleration
Acceleration
+3.3pp
Accelerating
Percentile
P38
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $12.74M | -69.7% |
| 2024 | $42.09M | +5.8% |
| 2023 | $39.81M | +101.0% |
| 2022 | $19.80M | +94.9% |
| 2021 | $10.16M | +14.9% |
| 2020 | $8.84M | -54.5% |
| 2019 | $19.41M | -53.5% |
| 2018 | $41.76M | +102.8% |
| 2017 | $20.59M | +0.6% |
| 2016 | $20.47M | - |